Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy

References

• Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560–575. doi:10.3978/j.issn.2218-6751.2015.06.06
   PubMed Web of Science ®Google Scholar
• Chirasuthat P, Chayavichitsilp P. Atezolizumab-induced Stevens-Johnson syndrome in a patient with non-small cell lung carcinoma. Case Rep Dermatol. 2018;10(2):198–202. doi:10.1159/000492172
   PubMedGoogle Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–1353. doi:10.1001/jamaoncol.2016.1051
   PubMed Web of Science ®Google Scholar
• Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management [Formula: see text]. J Cutan Med Surg. 2021;25(1):59–76. doi:10.1177/1203475420943260
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen G, He Z, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database. EClinicalMedicine. 2021;37:100951. doi:10.1016/j.eclinm.2021.100951
   PubMedGoogle Scholar
• Chiu YM, Chiu HY. Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019. Br J Dermatol. 2023;189:553–560. doi:10.1093/bjd/ljad234
   PubMed Web of Science ®Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J-C. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–96. doi:10.1001/archderm.1993.01680220104023
   PubMedGoogle Scholar
• Gong T, Zhang P, Ruan S-F, et al. APOA4 as a novel predictor of prognosis in Stevens-Johnson syndrome/toxic epidermal necrolysis: a proteomics analysis from two prospective cohorts. J Am Acad Dermatol. 2023;89(1):45–52. doi:10.1016/j.jaad.2023.02.058
   PubMed Web of Science ®Google Scholar
• Diphoorn J, Cazzaniga S, Gamba C, et al. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf. 2016;25(2):196–203. doi:10.1002/pds.3937
   PubMed Web of Science ®Google Scholar
• Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T. Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Rev Allergy Immunol. 2018;54(1):147–176. doi:10.1007/s12016-017-8654-z
   PubMed Web of Science ®Google Scholar
• Gibson A, Deshpande P, Campbell CN, et al. Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. J Allergy Clin Immunol. 2023;151(2):289–300.e4. doi:10.1016/j.jaci.2022.12.005
   PubMed Web of Science ®Google Scholar
• Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343–1350. doi:10.1038/nm.1884
   PubMed Web of Science ®Google Scholar
• Law EH, Leung M. Corticosteroids in Stevens-Johnson Syndrome/toxic epidermal necrolysis: current evidence and implications for future research. Ann Pharmacother. 2015;49(3):335–342. doi:10.1177/1060028014560012
   PubMed Web of Science ®Google Scholar
• Yamane Y, Matsukura S, Watanabe Y, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--treatment and outcome. Allergol Int. 2016;65(1):74–81. doi:10.1016/j.alit.2015.09.001
   PubMed Web of Science ®Google Scholar
• Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013;69(3):496–498. doi:10.1016/j.jaad.2013.04.007
   PubMed Web of Science ®Google Scholar
• Kridin K, Brüggen MC, Chua SL, et al. Assessment of treatment approaches and outcomes in Stevens-Johnson syndrome and toxic epidermal necrolysis: insights from a pan-European multicenter study. JAMA Dermatol. 2021;157(10):1182–1190. doi:10.1001/jamadermatol.2021.3154
   PubMed Web of Science ®Google Scholar
• Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985–996. doi:10.1172/JCI93349
   PubMed Web of Science ®Google Scholar
• Zhang J, Lu CW, Chen CB, et al. Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study. J Allergy Clin Immunol Pract. 2022;10(5):1295–1304.e6. doi:10.1016/j.jaip.2022.01.038
   PubMed Web of Science ®Google Scholar
• Chang HC, Wang TJ, Lin MH, Chen TJ. A review of the systemic treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis. Biomedicines. 2022;10:9. doi:10.3390/biomedicines10092105
   Web of Science ®Google Scholar
• Zhang J, Zhang P, Xu QY, Zhu YT, Chen W, Ji C. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma. Australas J Dermatol. 2022;63(1):e71–e74. doi:10.1111/ajd.13704
   PubMed Web of Science ®Google Scholar
• Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016;34(25):3023–3030. doi:10.1200/JCO.2015.65.9508
   PubMed Web of Science ®Google Scholar
• Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250–255. doi:10.1093/annonc/mdx642
   PubMed Web of Science ®Google Scholar
• Honda Y, Hattori Y, Katsura S, et al. Stevens-Johnson syndrome-like erosive dermatitis possibly related to Afatinib. Eur J Dermatol. 2016;26(4):413–414. doi:10.1684/ejd.2016.2807
   PubMed Web of Science ®Google Scholar
• Doesch J, Debus D, Meyer C, et al. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient. Lung Cancer. 2016;95:35–38. doi:10.1016/j.lungcan.2016.02.015
   PubMed Web of Science ®Google Scholar
• Lee SS, Chu PY. Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer. Am J Otolaryngol. 2010;31(4):288–290. doi:10.1016/j.amjoto.2009.02.021
   PubMed Web of Science ®Google Scholar
• Pantano F, Silletta M, Iovieno A, et al. Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitunumab. Int J Colorectal Dis. 2009;24(10):1247–1248. doi:10.1007/s00384-009-0676-4
   PubMed Web of Science ®Google Scholar
• Urosevic-Maiwald M, Harr T, French LE, Dummer R. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. Int J Dermatol. 2012;51(7):864–867. doi:10.1111/j.1365-4632.2011.05356.x
   PubMed Web of Science ®Google Scholar
• Lin WL, Lin WC, Yang JY, et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol. 2008;26(16):2779–2780. doi:10.1200/JCO.2007.15.7883
   PubMed Web of Science ®Google Scholar
• Huang JJ, Ma SX, Hou X, et al. Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer. Chin J Cancer. 2015;34(2):94–98. doi:10.5732/cjc.014.10151
   PubMedGoogle Scholar
• Wnorowski AM, de Souza A, Chachoua A, Cohen DE. The management of EGFR inhibitor adverse events: a case series and treatment paradigm. Int J Dermatol. 2012;51(2):223–232. doi:10.1111/j.1365-4632.2011.05082.x
   PubMed Web of Science ®Google Scholar
• Ladizinski B, Sankey C. A topical matter: toxic epidermal necrolysis. Am J Med. 2014;127(10):931–932. doi:10.1016/j.amjmed.2014.06.013
   PubMed Web of Science ®Google Scholar
• Yoon J, Oh CW, Kim CY. Stevens-Johnson syndrome induced by vandetanib. Ann Dermatol. 2011;23(Suppl 3):S343–5. doi:10.5021/ad.2011.23.S3.S343
   PubMed Web of Science ®Google Scholar
• Bois E, Holle LM, Farooq U. Late onset imatinib-induced Stevens-Johnson syndrome. J Oncol Pharm Pract. 2014;20(6):476–478. doi:10.1177/1078155213518226
   PubMed Web of Science ®Google Scholar
• Severino G, Chillotti C, De Lisa R, Del Zompo M, Ardau R. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother. 2005;39(1):162–164. doi:10.1345/aph.1E127
   PubMed Web of Science ®Google Scholar
• Rule SA, O’Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood. 2002;100(9):3434–3435. doi:10.1182/blood-2002-08-2431
   PubMed Web of Science ®Google Scholar
• Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002;117(3):620–622. doi:10.1046/j.1365-2141.2002.03499.x
   PubMed Web of Science ®Google Scholar
• Hsieh HJ, Chan AL, Lin SJ. Stevens-Johnson syndrome induced by combination of imatinib and allopurinol. Chemotherapy. 2009;55(4):197–199. doi:10.1159/000218097
   PubMed Web of Science ®Google Scholar
• Jha P, Himanshu D, Jain N, Singh AK. Imatinib-induced Stevens-Johnson syndrome. BMJ Case Rep. 2013;2013:1.
   Google Scholar
• Schaich M, Schäkel K, Illmer T, Ehninger G, Bornhäuser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2003;82(5):303–304. doi:10.1007/s00277-003-0643-z
   PubMed Web of Science ®Google Scholar
• Mahapatra M, Mishra P, Kumar R. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol. 2007;86(7):537–538. doi:10.1007/s00277-007-0265-y
   PubMed Web of Science ®Google Scholar
• Pavithran K, Thomas M. Imatinib induced Stevens-Johnson syndrome: lack of recurrence following re-challenge with a lower dose. Indian J Dermatol Venereol Leprol. 2005;71(4):288–289. doi:10.4103/0378-6323.16628
   PubMedGoogle Scholar
• Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood. 2003;101(6):2446. doi:10.1182/blood-2002-12-3696
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Rule SA. Position paper on imatinib mesylate in chronic myeloid leukaemia. Br J Haematol. 2002;119(1):268–272. doi:10.1046/j.1365-2141.2002.39201.x
   PubMed Web of Science ®Google Scholar
• Sohn KH, Oh SY, Lim KW, Kim MY, Lee SY, Kang HR. Sorafenib induces delayed-onset cutaneous hypersensitivity: a case series. Allergy Asthma Immunol Res. 2015;7(3):304–307. doi:10.4168/aair.2015.7.3.304
   PubMed Web of Science ®Google Scholar
• Choi MK, Woo HY, Heo J, et al. Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma. Ann Dermatol. 2011;23(Suppl 3):S404–7. doi:10.5021/ad.2011.23.S3.S404
   PubMedGoogle Scholar
• Ikeda M, Fujita T, Amoh Y, Mii S, Matsumoto K, Iwamura M. Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma. Urol Int. 2013;91(4):482–483. doi:10.1159/000351918
   PubMed Web of Science ®Google Scholar
• Fang B, Song Y, Ma J, Zhao RC. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma. Acta Haematol. 2007;118(2):65–67. doi:10.1159/000102604
   PubMed Web of Science ®Google Scholar
• Rui X, Meidan W, Gongqiang W, et al. Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review. Front Oncol. 2023;13:1227448. doi:10.3389/fonc.2023.1227448
   PubMed Web of Science ®Google Scholar
• Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol. 2009;27(1):156–157. doi:10.1200/JCO.2008.20.3737
   PubMed Web of Science ®Google Scholar
• Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol. 2002;13(12):1948–1950. doi:10.1093/annonc/mdf350
   PubMed Web of Science ®Google Scholar
• Fallon MJ, Heck JN. Fatal Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol-rituximab-bendamustine therapy. J Oncol Pharm Pract. 2015;21(5):388–392. doi:10.1177/1078155214533368
   PubMed Web of Science ®Google Scholar
• Parise L, Kahle J, Schlaak M, Mauch C, Kurschat P. Reply to Rituxan is not associated with Stevens-Johnson syndrome. Ann Oncol. 2012;23(3):807. doi:10.1093/annonc/mdr629
   PubMed Web of Science ®Google Scholar
• Del Principe MI, Sconocchia G, Buccisano F, et al. Extensive toxic epidermal necrolysis following brentuximab vedotin administration. Ann Hematol. 2015;94(2):355–356. doi:10.1007/s00277-014-2148-3
   PubMed Web of Science ®Google Scholar
• Kılıç S, Özkaya E, Baykal C, Vatansever S. Vemurafenib-induced toxic epidermal necrolysis: is it an emerging side-effect of the drug? J Eur Acad Dermatol Venereol. 2017;31(8):e354–e355. doi:10.1111/jdv.14150
   PubMed Web of Science ®Google Scholar
• Minor DR, Rodvien R, Kashani-Sabet M. Successful desensitization in a case of Stevens-Johnson syndrome due to vemurafenib. Melanoma Res. 2012;22(5):410–411. doi:10.1097/CMR.0b013e3283573437
   PubMed Web of Science ®Google Scholar
• Bellón T, Lerma V, González-Valle O, González Herrada C, de Abajo FJ. Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds. Br J Dermatol. 2016;174(3):621–624. doi:10.1111/bjd.14201
   PubMed Web of Science ®Google Scholar
• Arenbergerova M, Mrazova I, Horazdovsky J, Sticova E, Fialova A, Arenberger P. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure. J Eur Acad Dermatol Venereol. 2017;31(5):e253–e254. doi:10.1111/jdv.14010
   PubMed Web of Science ®Google Scholar
• Jeudy G, Dalac-Rat S, Bonniaud B, et al. Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br J Dermatol. 2015;172(5):1454–1455. doi:10.1111/bjd.13522
   PubMed Web of Science ®Google Scholar
• Sinha R, Lecamwasam K, Purshouse K, Reed J, Middleton MR, Fearfield L. Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma. Br J Dermatol. 2014;170(4):997–999. doi:10.1111/bjd.12796
   PubMed Web of Science ®Google Scholar
• Wiener JS, Tucker JA, Walther PJ. Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis. South Med J. 1992;85(6):656–659. doi:10.1097/00007611-199206000-00020
   PubMed Web of Science ®Google Scholar
• Polder K, Wang C, Duvic M, et al. Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leuk Lymphoma. 2005;46(12):1807–1811. doi:10.1080/10428190500233764
   PubMed Web of Science ®Google Scholar
• Dika E, Ravaioli GM, Fanti PA, et al. Cutaneous adverse effects during ipilimumab treatment for metastatic melanoma: a prospective study. Eur J Dermatol. 2017;27(3):266–270. doi:10.1684/ejd.2017.3023
   PubMed Web of Science ®Google Scholar
• Lee O, Masood M, Nutan F. Case series of Stevens-Johnson syndrome and toxic epidermal necrolysis with nivolumab and nivolumab/ ipilimumab combination therapy in metastatic melanoma. J Drugs Dermatol. 2022;21(5):529–530. doi:10.36849/JDD.6559
   PubMed Web of Science ®Google Scholar
• Nayar N, Briscoe K, Fernandez Penas P. Toxic epidermal necrolysis-like reaction with satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother. 2016;39(3):149–152. doi:10.1097/CJI.0000000000000112
   PubMed Web of Science ®Google Scholar
• Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381–384. doi:10.1111/cup.12876
   PubMed Web of Science ®Google Scholar
• Lin YT, Yang JC, Chu CY. Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. Lung Cancer. 2020;148:177–178. doi:10.1016/j.lungcan.2020.09.001
   PubMed Web of Science ®Google Scholar
• Kim MC, Khan HN. Nivolumab-induced toxic epidermal necrolysis: rare but fatal complication of immune checkpoint inhibitor therapy. Cureus. 2021;13(5):e15017. doi:10.7759/cureus.15017
   PubMed Web of Science ®Google Scholar
• Ito J, Fujimoto D, Nakamura A, et al. Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer. 2017;109:58–61. doi:10.1016/j.lungcan.2017.04.020
   PubMed Web of Science ®Google Scholar
• Dasanu CA. Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma. J Oncol Pharm Pract. 2019;25(8):2052–2055. doi:10.1177/1078155219830166
   PubMed Web of Science ®Google Scholar
• Salati M, Pifferi M, Baldessari C, et al. Stevens-Johnson syndrome during nivolumab treatment of NSCLC. Ann Oncol. 2018;29(1):283–284. doi:10.1093/annonc/mdx640
   PubMed Web of Science ®Google Scholar
• Shah KM, Rancour EA, Al-Omari A, Rahnama-Moghadam S. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome. Dermatol Online J. 2018;24:6.
   Google Scholar
• Rodríguez-Otero N, Chamorro-Pérez J, Fernández-Lozano C, et al. Nivolumab-induced Stevens-Johnson syndrome: not only due to PD-1 inhibition. J Allergy Clin Immunol Pract. 2023;11(9):2936–2938.e1. doi:10.1016/j.jaip.2023.06.008
   PubMed Web of Science ®Google Scholar
• Rouyer L, Bursztejn AC, Charbit L, Schmutz JL, Moawad S. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. Eur J Dermatol. 2018;28(3):380–381. doi:10.1684/ejd.2018.3295
   PubMed Web of Science ®Google Scholar
• Hwang A, Iskandar A, Dasanu CA. Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy. J Oncol Pharm Pract. 2019;25(6):1520–1522. doi:10.1177/1078155218791314
   PubMed Web of Science ®Google Scholar
• Kian W, Zemel M, Elobra F, et al. Intravenous immunoglobulin efficacy on pembrolizumab induced severe toxic epidermal necrolysis. Anticancer Drugs. 2022;33(1):e738–e740. doi:10.1097/CAD.0000000000001162
   PubMed Web of Science ®Google Scholar
• Ryu S, Jun I, Kim TI, Seo KY, Kim EK. Pembrolizumab-induced Stevens-Johnson syndrome with severe ocular complications. Ocul Immunol Inflamm. 2022;30(6):1533–1535. doi:10.1080/09273948.2021.1896006
   PubMed Web of Science ®Google Scholar
• Neema S, Sathu S, Vasudevan B, Shreshta S, Bhatt S, K L. Pembrolizumab-induced toxic epidermal necrolysis: a rare cause of severe adverse drug reaction. Indian J Dermatol Venereol Leprol. 2023;89(4):589–591. doi:10.25259/IJDVL_612_2022
   PubMed Web of Science ®Google Scholar
• Saw S, Lee HY, Ng QS. Pembrolizumab-induced Stevens-Johnson syndrome in non-melanoma patients. Eur J Cancer. 2017;81:237–239. doi:10.1016/j.ejca.2017.03.026
   PubMed Web of Science ®Google Scholar
• Bhardwaj M, Chiu MN, Pilkhwal Sah S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022;41(1):73–90. doi:10.1080/15569527.2022.2034842
   PubMed Web of Science ®Google Scholar
• Cai ZR, Lecours J, Adam JP, et al. Toxic epidermal necrolysis associated with pembrolizumab. J Oncol Pharm Pract. 2020;26(5):1259–1265. doi:10.1177/1078155219890659
   PubMed Web of Science ®Google Scholar
• Liniker E, Menzies AM, Kong BY, et al. Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016;5(9):e1214788. doi:10.1080/2162402X.2016.1214788
   PubMed Web of Science ®Google Scholar
• Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22(16):4023–4029. doi:10.1158/1078-0432.CCR-15-2872
   PubMed Web of Science ®Google Scholar
• Li G, Gong S, Wang N, Yao X. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: a case report. Front Immunol. 2022;13:989966. doi:10.3389/fimmu.2022.989966
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang L, Cheng Q, Lei X, Wu J, Chen N. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review. Immunotherapy. 2023;15(15):1249–1256. doi:10.2217/imt-2023-0081
   PubMed Web of Science ®Google Scholar
• Sato I, Mizuno H, Kataoka N, et al. Osimertinib-associated toxic epidermal necrolysis in a lung cancer patient harboring an EGFR mutation-a case report and a review of the literature. Medicina. 2020;56:8.
   Google Scholar
• Yang W, Xu X, Xia D, Wang H, Jiang J, Yang G. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review. Immunotherapy. 2022;14(5):275–282. doi:10.2217/imt-2021-0074
   PubMed Web of Science ®Google Scholar
• Sommers KR, Kong KM, Bui DT, Fruehauf JP, Holcombe RF. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs. 2003;14(8):659–662. doi:10.1097/00001813-200309000-00012
   PubMed Web of Science ®Google Scholar
• Sendur MA, Kilickap S. Stevens–Johnson syndrome after treatment with capecitabine. Clin Oncol. 2008;20(2):202–203. doi:10.1016/j.clon.2007.11.005
   Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019–1024. doi:10.1001/archderm.138.8.1019
   PubMedGoogle Scholar
• Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–153. doi:10.1046/j.1523-1747.2000.00061.x
   PubMed Web of Science ®Google Scholar
• Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60–68. doi:10.1038/clpt.2009.252
   PubMed Web of Science ®Google Scholar
• Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013;14(4):327–333. doi:10.1007/s40257-013-0021-0
   PubMed Web of Science ®Google Scholar
• Yang SC, Hu S, Zhang SZ, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in China. J Immunol Res. 2018;2018:4320195. doi:10.1155/2018/4320195
   PubMed Web of Science ®Google Scholar
• Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92(1):62–66. doi:10.2340/00015555-1169
   PubMed Web of Science ®Google Scholar
• Teng YS, Yu S. Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. Curr Oncol. 2023;30(7):6805–6819. doi:10.3390/curroncol30070498
   PubMed Web of Science ®Google Scholar
• Viard-Leveugle I, Gaide O, Jankovic D, et al. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133(2):489–498. doi:10.1038/jid.2012.330
   PubMed Web of Science ®Google Scholar
• Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005;116(4):923–924. doi:10.1016/j.jaci.2005.06.029
   PubMed Web of Science ®Google Scholar
• Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;84(2):390–397. doi:10.1016/j.jaad.2020.08.122
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514–522. doi:10.1001/jamadermatol.2016.5668
   PubMed Web of Science ®Google Scholar
• Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of high-dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome. Int Ophthalmol Clin. 2005;45(4):25–48. doi:10.1097/01.iio.0000177430.89645.6d
   PubMedGoogle Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Shah JV, Parekh JM, Shah PA, Shah PV, Sanyal M, Shrivastav PS. Application of an LC-MS/MS method for the analysis of amlodipine, valsartan and hydrochlorothiazide in polypill for a bioequivalence study. J Pharm Anal. 2017;7(5):309–316. doi:10.1016/j.jpha.2017.06.001
   PubMed Web of Science ®Google Scholar
• Osawa K, Kiniwa Y, Shimosato Y, et al. Toxic epidermal necrolysis caused by apalutamide: a case report of treatment using etanercept with conventional steroid therapy. Acta Derm Venereol. 2022;102:adv00723. doi:10.2340/actadv.v102.2243
   PubMed Web of Science ®Google Scholar
• Ben-Eltriki M, Deb S, Guns ES. Calcitriol in combination therapy for prostate cancer: pharmacokinetic and pharmacodynamic interactions. J Cancer. 2016;7(4):391–407. doi:10.7150/jca.13470
   PubMed Web of Science ®Google Scholar
• Mamza J, Mehta R, Donnelly R, Idris I. Comparative efficacy of adding sitagliptin to metformin, sulfonylurea or dual therapy: a propensity score-weighted cohort study. Diabetes Ther. 2015;6(2):213–226. doi:10.1007/s13300-015-0110-6
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Guttman-Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm. Adv Ther. 2017;34(7):1594–1609. doi:10.1007/s12325-017-0542-7
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806–815. doi:10.1093/ecco-jcc/jjv096
   PubMed Web of Science ®Google Scholar
• Kherlopian A, Mewton E, Fong G, Fischer G. Highlighting Adalimumab as a treatment option for systemic treatment of toxic epidermal necrolysis: a case series from a tertiary specialised burns centre. Australas J Dermatol. 2022;63(4):497–504. doi:10.1111/ajd.13911
   PubMed Web of Science ®Google Scholar